1
|
Nguyen TU, Hurh S, In S, Nguyen LP, Cho M, Mykhailova K, Kim HR, Ham BJ, Choi Y, Kim WK, Hwang JI. SP-8356 inhibits acute lung injury by suppressing inflammatory cytokine production and immune cell infiltration. Int Immunopharmacol 2024; 131:111847. [PMID: 38518593 DOI: 10.1016/j.intimp.2024.111847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 03/08/2024] [Accepted: 03/09/2024] [Indexed: 03/24/2024]
Abstract
This study investigated the anti-inflammatory and protective properties of SP-8356, a synthetic derivative of (1S)-(-)-verbenone, in a mouse model of LPS-induced acute lung injury (ALI). By targeting intracellular signaling pathways and inflammatory responses, SP-8356 demonstrated a potent ability to attenuate deleterious effects of proinflammatory stimuli. Specifically, SP-8356 effectively inhibited the activation of crucial signaling molecules such as NF-κB and Akt, and subsequently dampened the expression of inflammatory cytokines in various lung cellular components. Intervention with SP-8356 treatment also preserved the structural integrity of the epithelial and endothelial barriers. By reducing immune cell infiltration into inflamed lung tissue, SP-8356 exerted a broad protective effect against ALI. These findings position SP-8356 as a promising therapeutic candidate for pulmonary inflammatory diseases that cause ALI.
Collapse
Affiliation(s)
- Thai-Uy Nguyen
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Sunghoon Hurh
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Soyeon In
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Lan Phuong Nguyen
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Minyeong Cho
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Kateryna Mykhailova
- Department of Biotechnology, College of Life Sciences Biotechnology, Korea University, Seoul 02841, Republic of Korea
| | - Hong-Rae Kim
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Byung-Joo Ham
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Psychiatry, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Yongseok Choi
- Department of Biotechnology, College of Life Sciences Biotechnology, Korea University, Seoul 02841, Republic of Korea
| | - Won-Ki Kim
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea; Institute for Inflammation Control, Korea University, Seoul 02841, Republic of Korea.
| | - Jong-Ik Hwang
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Republic of Korea.
| |
Collapse
|
2
|
Mathur A, Meena A, Luqman S. Monoterpenoids: An upcoming class of therapeutic agents for modulating cancer metastasis. Phytother Res 2024; 38:939-969. [PMID: 38102850 DOI: 10.1002/ptr.8081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 10/28/2023] [Accepted: 11/14/2023] [Indexed: 12/17/2023]
Abstract
Monoterpenoids, a sub-class of terpenoids, are secondary metabolites frequently extracted from the essential oils of aromatic plants. Their antitumor properties including antiproliferative, apoptotic, antiangiogenic, and antimetastatic effects along with other biological activities have been the subject of extensive study due to their diverse characteristics. In recent years, numerous investigations have been conducted to understand its potential anticancer impacts, specifically focusing on antiproliferative and apoptotic mechanisms. Metastasis, a malignancy hallmark, can exert either protective or destructive influences on tumor cells. Despite this, the potential antimetastatic and antiangiogenic attributes of monoterpenoids need further exploration. This review focuses on specific monoterpenoids, examining their effects on metastasis and relevant signaling pathways. The monoterpenoids exhibit a high level of complexity as natural products that regulate metastatic proteins through various signaling pathways, including phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin, mitogen-activated protein kinase/extracellular signal-regulated kinase/jun N-terminal kinase, nuclear factor kappa B, vascular endothelial growth factor, and epithelial mesenchymal transition process. Additionally, this review delves into the biosynthesis and classification of monoterpenoids, their potential antitumor impacts on cell lines, the plant sources of monoterpenoids, and the current status of limited clinical trials investigating their efficacy against cancer. Moreover, monoterpenoids depict promising potential in preventing cancer metastasis, however, inadequate clinical trials limit their drug usage. State-of-the-art techniques and technologies are being employed to overcome the challenges of utilizing monoterpenoids as an anticancer agent.
Collapse
Affiliation(s)
- Anurag Mathur
- Bioprospection and Product Development Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| | - Abha Meena
- Bioprospection and Product Development Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| | - Suaib Luqman
- Bioprospection and Product Development Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| |
Collapse
|
3
|
Yang L, Hu L. SP-8356: A Novel Verbenone Derivative Exerts In Vitro Anti-Non-Small Cell Lung Cancer Effects, Promotes Apoptosis via The P53/MDM2 Axis and Inhibits Tumor Formation in Mice. CELL JOURNAL 2023; 25:839-846. [PMID: 38192254 PMCID: PMC10777321 DOI: 10.22074/cellj.2023.2008708.1385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 09/19/2023] [Accepted: 10/28/2023] [Indexed: 01/10/2024]
Abstract
OBJECTIVE Non-small cell lung cancer (NSCLC) stands as a prominent contributor to cancer-related fatalities on a global scale, necessitating the search for novel therapeutic agents. SP-8356, a derivative of (1S)-(-)-verbenone, has shown promise as an anticancer agent in preclinical studies. However, specific mechanisms underlying its effects in NSCLC remain to be elucidated. The aim of this research was to explore the in vitro anti-NSCLC effects of SP-8356, elucidate its mechanisms of action, and assess its efficacy in inhibiting tumor formation in a murine model. MATERIALS AND METHODS In this experimental study, NSCLC cell lines were treated with various concentrations of SP- 8356. Cell viability and proliferation were assessed using MTT and colony formation assays, respectively. Cell cycle distribution was analyzed by flow cytometry, and apoptosis was evaluated by determining apoptotic protein expression. Western blot analysis was conducted to assess protein expression levels of the both p53 and MDM2. Additionally, we evaluated efficacy of the SP-8356 in inhibiting tumor formation of the nude mouse model. RESULTS SP-8356 demonstrated a concentration-dependent inhibition of cell proliferation in the NSCLC cell lines. Flow cytometric analysis showed that SP-8356 led to cell cycle arrest at the G2/M phase, indicating its potential influence on regulating the cell cycle. SP-8356 treatment was associated with the downregulation of CDK1 and Cyclin B1. Additionally, SP-8356 significantly enhanced apoptosis in NSCLC cells. SP-8356 treatment was associated with the downregulation of Bcl-2, while Bax expression was upregulated. Mechanistically, SP-8356 led to accumulation of the p53 protein levels within the NSCLC cells. This accumulation was mediated through inhibition of its negative regulator, MDM2. Using a nude mouse model demonstrated that SP-8356 effectively inhibited tumor formation in vivo. CONCLUSION Our findings shed light on the molecular mechanisms underlying anticancer activity of SP-8356 and highlight its potential as a promising therapeutic candidate for NSCLC treatment.
Collapse
Affiliation(s)
- Lei Yang
- Department of Clinical Laboratory, People's Hospital of Chongqing Liang jiang New Area, Chongqing, China
| | - Liyi Hu
- Department of Clinical Laboratory, People's Hospital of Chongqing Liang jiang New Area, Chongqing, China.
| |
Collapse
|
4
|
Manhas RS, Koul D, Kumar P, Kumar A, Bhagat A, Madishetti S, Sangwan PL, Ahmed Z, Chaubey A. Talaromyces purpurogenus MRS-F13 catalyzed biotransformation of (-)-verbenone to (-)-10-hydroxyverbenone and their anti-inflammatory activity profile. BIOCATAL BIOTRANSFOR 2022. [DOI: 10.1080/10242422.2022.2138359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Ravi S. Manhas
- Fermentation & Microbial Biotechnology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
- Academy of Scientific and Innovative Research, CSIR-Human Resource Development Centre, Campus Ghaziabad, India
| | - Diksha Koul
- Fermentation & Microbial Biotechnology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
- Academy of Scientific and Innovative Research, CSIR-Human Resource Development Centre, Campus Ghaziabad, India
| | - Parveen Kumar
- Academy of Scientific and Innovative Research, CSIR-Human Resource Development Centre, Campus Ghaziabad, India
- Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
| | - Amit Kumar
- Quality Management &Instrumentation Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
| | - Asha Bhagat
- Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
| | - Sreedhar Madishetti
- Academy of Scientific and Innovative Research, CSIR-Human Resource Development Centre, Campus Ghaziabad, India
- Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
| | - Payare L. Sangwan
- Academy of Scientific and Innovative Research, CSIR-Human Resource Development Centre, Campus Ghaziabad, India
- Natural Products & Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
| | - Zabeer Ahmed
- Academy of Scientific and Innovative Research, CSIR-Human Resource Development Centre, Campus Ghaziabad, India
- Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
| | - Asha Chaubey
- Fermentation & Microbial Biotechnology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India
| |
Collapse
|
5
|
Huang B, Zhang X, Cao Q, Chen J, Lin C, Xiang T, Zeng P. Construction and validation of a prognostic risk model for breast cancer based on protein expression. BMC Med Genomics 2022; 15:148. [PMID: 35787690 PMCID: PMC9252042 DOI: 10.1186/s12920-022-01299-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Accepted: 06/23/2022] [Indexed: 11/17/2022] Open
Abstract
Breast cancer (BRCA) is the primary cause of mortality among females globally. The combination of advanced genomic analysis with proteomics characterization to construct a protein prognostic model will help to screen effective biomarkers and find new therapeutic directions. This study obtained proteomics data from The Cancer Proteome Atlas (TCPA) dataset and clinical data from The Cancer Genome Atlas (TCGA) dataset. Kaplan–Meier and Cox regression analyses were used to construct a prognostic risk model, which was consisted of 6 proteins (CASPASE7CLEAVEDD198, NFKBP65-pS536, PCADHERIN, P27, X4EBP1-pT70, and EIF4G). Based on risk curves, survival curves, receiver operating characteristic curves, and independent prognostic analysis, the protein prognostic model could be viewed as an independent factor to accurately predict the survival time of BRCA patients. We further validated that this prognostic model had good predictive performance in the GSE88770 dataset. The expression of 6 proteins was significantly associated with the overall survival of BRCA patients. The 6 proteins and encoding genes were differentially expressed in normal and primary tumor tissues and in different BRCA stages. In addition, we verified the expression of 3 differential proteins by immunohistochemistry and found that CDH3 and EIF4G1 were significantly higher in breast cancer tissues. Functional enrichment analysis indicated that the 6 genes were mainly related to the HIF-1 signaling pathway and the PI3K-AKT signaling pathway. This study suggested that the prognosis-related proteins might serve as new biomarkers for BRCA diagnosis, and that the risk model could be used to predict the prognosis of BRCA patients.
Collapse
Affiliation(s)
- Bo Huang
- Department of Gynecology and Obstetrics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Xujun Zhang
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Qingyi Cao
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Jianing Chen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Chenhong Lin
- Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Tianxin Xiang
- Department of Hospital Infection Control, The First Affiliated Hospital of Nanchang University, 17 Yongwai Road, Donghu District, Nanchang, China
| | - Ping Zeng
- Department of Hospital Infection Control, The First Affiliated Hospital of Nanchang University, 17 Yongwai Road, Donghu District, Nanchang, China.
| |
Collapse
|
6
|
Pahk K, Lee SG, Joung C, Kim EO, Kwon HW, Kim DH, Hwang JI, Kim S, Kim WK. SP-1154, a novel synthetic TGF-β inhibitor, alleviates obesity and hepatic steatosis in high-fat diet-induced mice. Biomed Pharmacother 2021; 145:112441. [PMID: 34813997 DOI: 10.1016/j.biopha.2021.112441] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Revised: 11/08/2021] [Accepted: 11/16/2021] [Indexed: 12/14/2022] Open
Abstract
OBJECTIVE Obesity-induced inflamed visceral adipose tissue (VAT) secretes pro-inflammatory cytokines thereby promoting systemic inflammation and insulin resistance which further exacerbate obesity-associated nonalcoholic fatty liver disease (NAFLD). Transforming growth factor (TGF)-β /Smad3 signaling plays a crucial role in the inflammatory events within the VAT. Here, we investigate whether SP-1154, a novel synthetic verbenone derivative, can inhibit TGF-β/Smad3 signaling thereby exhibiting a therapeutic effect against obesity-induced inflamed VAT and subsequent NAFLD in high-fat diet-induced mice. METHODS NAFLD was induced by a high-fat diet (60% fat) for 20 weeks using the male C57BL/6 mice. SP-1154 (50 mg/kg) was orally given daily for 20 weeks. In vivo VAT- and systemic inflammation were measured by using 18F-fluorodeoxyglucose positron emission tomography and C-reactive protein levels. Both insulin tolerance- and glucose tolerance test were performed to assess the status of insulin resistance and glucose intolerance. Histological and molecular analyses were performed on harvested liver and VAT. KEY FINDINGS SP-1154 inhibited TGF-β/Smad3 signaling pathway and remarkably suppressed high-fat diet-induced VAT inflammation and its related systemic inflammation. Furthermore, SP-1154 significantly improved insulin sensitivity with glucose homeostasis and reduced hepatic steatosis. SP-1154 significantly improves VAT inflammation and obesity-related NAFLD. CONCLUSION Our novel findings support the potential use of SP-1154 as a therapeutic drug for obesity and its related NAFLD by targeting the inflamed VAT.
Collapse
Affiliation(s)
- Kisoo Pahk
- Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, South Korea
| | - Sang Gil Lee
- Institute for Inflammation Control, Korea University, Seoul, South Korea; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, South Korea
| | - Chanmin Joung
- Institute for Inflammation Control, Korea University, Seoul, South Korea
| | - Eun-Ok Kim
- Medcial Science Research Center, College of Medicine, Korea University, Seoul, South Korea
| | - Hyun Woo Kwon
- Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, South Korea
| | - Dong Hwi Kim
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul, South Korea
| | - Jong-Ik Hwang
- Department of Biomedical Sciences, College of Medicine, Korea University, Seoul, South Korea
| | - Sungeun Kim
- Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, South Korea
| | - Won-Ki Kim
- Institute for Inflammation Control, Korea University, Seoul, South Korea.
| |
Collapse
|
7
|
Zhou J, Liu K, Feng C, Peng Z, Luo W. Therapeutic effect of SP-8356 on pulmonary embolism-associated cardiac injury is mediated by its ability to suppress apoptosis and inflammation. J Cell Mol Med 2021; 25:5260-5268. [PMID: 33942476 PMCID: PMC8178275 DOI: 10.1111/jcmm.16535] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 03/06/2021] [Accepted: 03/22/2021] [Indexed: 12/11/2022] Open
Abstract
The cyclophilin A–CD147 interaction has been reported to be one of the most potential therapeutic targets for the treatment of acute pulmonary embolism. The signalling of extracellular signal‐regulated kinase 1/2 (ERK1/2) was also reported in the pathogenesis of cardiac injury. Since SP‐8356 is regarded as a novel Inhibitor of CD147‐Cyclophilin, the study aimed to evaluate potential therapeutic effects of SP‐8356 for pulmonary embolism‐associated cardiac injury. Western blot and immunohistochemistry were carried out to analyse the expression of MMP‐9, ERK1/2, phosphorylated ERK1/2 (p‐ERK1/2), P65, p‐P65, and CyA protein in PE cell and rat models under distinct conditions. Flow cytometry and TUNEL were carried out to examine the apoptosis of primary rat myocardiocytes and PE rat models under distinct conditions. CyA treatment on primary rat myocardiocytes remarkably raised the expression of MMP‐9, p‐ERK1/2 and p‐P65 protein expression; SP8536 treatment effectively restored the CyA‐induced up‐regulation of MMP‐9, p‐ERK1/2 and p‐P65 protein expression in primary rat myocardiocytes. Besides, flow cytometry analysis showed that SP8536 remarkably suppressed the CyA‐induced elevation of cell apoptosis rate of primary rat myocardiocytes. Moreover, SP8536 notably diminished the abnormal elevation of right ventricular systolic pressure (RVSP), Troponin I and Myeloperoxidase activity in PE rat models. Furthermore, SP‐8536 significantly restored the up‐regulation of MMP‐9, p‐ERK1/2, p‐P65, CyA protein and the cellular apoptosis in the PE rat model. Our study validated that SP‐8356 could suppress cell apoptosis and inflammatory response via down‐regulating the highly expressed MMP‐9, p‐ERK1/2, and p‐P65 and MMP‐9 in PE‐associated cardiac injury in a dose‐dependent manner.
Collapse
Affiliation(s)
- Jia Zhou
- Department of Emergency, The First Affiliated Hospital of South China University, Hengyang, China
| | - Kai Liu
- Department of Pharmacology, The Central Hospital of Hengyang, Hengyang, China
| | - Cheng Feng
- Department of Emergency, The First Affiliated Hospital of South China University, Hengyang, China
| | - Zhengliang Peng
- Department of Emergency, The First Affiliated Hospital of South China University, Hengyang, China
| | - Wei Luo
- Department of Cardiovascular Medicine, The First Affiliated Hospital of South China University, Hengyang, China
| |
Collapse
|
8
|
Kim DH, Yong HJ, Mander S, Nguyen HT, Nguyen LP, Park HK, Cha HK, Kim WK, Hwang JI. SP-8356, a (1S)-(-)-Verbenone Derivative, Inhibits the Growth and Motility of Liver Cancer Cells by Regulating NF-κB and ERK Signaling. Biomol Ther (Seoul) 2021; 29:331-341. [PMID: 33455945 PMCID: PMC8094067 DOI: 10.4062/biomolther.2020.200] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 12/07/2020] [Accepted: 12/10/2020] [Indexed: 01/10/2023] Open
Abstract
Liver cancer is a common tumor and currently the second leading cause of cancer-related mortality globally. Liver cancer is highly related to inflammation as more than 90% of liver cancer arises in the context of hepatic inflammation, such as hepatitis B virus and hepatitis C virus infection. Despite significant improvements in the therapeutic modalities for liver cancer, patient prognosis is not satisfactory due to the limited efficacy of current drug therapies in anti-metastatic activity. Therefore, developing new effective anti-cancer agents with anti-metastatic activity is important for the treatment of liver cancer. In this study, SP-8356, a verbenone derivative with anti-inflammatory activity, was investigated for its effect on the growth and migration of liver cancer cells. Our findings demonstrated that SP-8356 inhibits the proliferation of liver cancer cells by inducing apoptosis and suppressing the mobility and invasion ability of liver cancer cells. Functional studies revealed that SP-8356 inhibits the mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways, which are related to cell proliferation and metastasis, resulting in the downregulation of metastasis-related genes. Moreover, using an orthotopic liver cancer model, tumor growth was significantly decreased following treatment with SP-8356. Thus, this study suggests that SP-8356 may be a potential agent for the treatment of liver cancer with multimodal regulation.
Collapse
Affiliation(s)
- Dong Hwi Kim
- Department of Biomedical Science, Korea University College of Medicine, Seoul 02841, Republic of Korea
| | - Hyo Jeong Yong
- Department of Biomedical Science, Korea University College of Medicine, Seoul 02841, Republic of Korea
| | - Sunam Mander
- Department of Biomedical Science, Korea University College of Medicine, Seoul 02841, Republic of Korea
| | - Huong Thi Nguyen
- Department of Biomedical Science, Korea University College of Medicine, Seoul 02841, Republic of Korea
| | - Lan Phuong Nguyen
- Department of Biomedical Science, Korea University College of Medicine, Seoul 02841, Republic of Korea
| | - Hee-Kyung Park
- Department of Biomedical Science, Korea University College of Medicine, Seoul 02841, Republic of Korea
| | - Hyo Kyeong Cha
- Department of Biomedical Science, Korea University College of Medicine, Seoul 02841, Republic of Korea
| | - Won-Ki Kim
- Department of Biomedical Science, Korea University College of Medicine, Seoul 02841, Republic of Korea.,Department of Neuroscience, Korea University College of Medicine, Seoul 02841, Republic of Korea
| | - Jong-Ik Hwang
- Department of Biomedical Science, Korea University College of Medicine, Seoul 02841, Republic of Korea
| |
Collapse
|
9
|
Grover M, Behl T, Sanduja M, Habibur Rahman M, Ahmadi A. Exploring the Potential of Aromatherapy as an Adjuvant Therapy in Cancer and its Complications: A Comprehensive Update. Anticancer Agents Med Chem 2021; 22:629-653. [PMID: 33563202 DOI: 10.2174/1871520621666210204201937] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 11/19/2020] [Accepted: 11/28/2020] [Indexed: 12/24/2022]
Abstract
BACKGROUND Aromatherapy is a traditional practice of employing essential oils for the therapeutic purposes, currently headed under the category of complementary and adjuvant medicine. OBJECTIVE The aim of this review article is to summarize the potential health benefits of aromatic essential oil from traditional times till the present. It also proposed some mechanisms which can be utilized as basis for using aromatherapy in cancer and cancer linked complications. METHODS To find out the relevant and authentic data, several search engines like Science direct, Pubmed, research gate, etc. were thoroughly checked by inserting key words like aromatherapy, complementary, adjuvant therapy etc. to collect the relevant material in context of article. Also, the chemical components of essential oil were classified based on the presence of functional groups, which are further explored for their cytotoxic potential. RESULTS The result depicted the anti-cancer potential of chemical constituents of essential oil against different types of cancer. Moreover, the essential oils show promising anti-inflammatory, anti-microbial, anti-oxidant and anti-mutagenic potential in several studies, which collectively can form the basis for initiation of its anti-cancer utility. CONCLUSION Aromatherapy can serve as adjuvant economic therapy in cancer after the standardization of protocol.
Collapse
Affiliation(s)
- Madhuri Grover
- B.S. Anangpuria Institute of Pharmacy, Faridabad, Haryana, . India
| | - Tapan Behl
- Chitkara College of Pharmacy, Chitkara University, Punjab, . India
| | | | - Md Habibur Rahman
- Department of Global Medical Science, Wonju College of Medicine, Yonsei University, . South Korea
| | - Amirhossein Ahmadi
- Pharmaceutical Sciences Research Centre, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari. Iran
| |
Collapse
|
10
|
Pacheco-Hernández Y, Sánchez-Hernández GR, Reyes-Cervantes E, Romero-Arenas O, Pérez-Xochipa I, Villa-Ruano N. Chemical Variation and Pharmacological Properties of Dyssodia decipiens Essential Oil. Chem Biodivers 2020; 17:e2000487. [PMID: 32749064 DOI: 10.1002/cbdv.202000487] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Accepted: 08/03/2020] [Indexed: 01/05/2023]
Abstract
Dyssodia decipiens is one of the seven recognized species within the Dyssodia genus, which has economic and social relevance in Mexico. Herein, we report on the volatile characterization and pharmacological activity of D. decipiens. The essential oils (2017-2019) contained verbenone (30.8-60.9 %), limonene (5.6-35.5 %), β-caryophyllene (7.8-19.8 %) and linalool (4.5-12.4 %) as major constituents along the studied years. Antifungal properties were probed on Candida albicans ATCC 90028, ATCC 10231 (fluconazole resistant) and five clinical isolates (IS1-IS5). Flower essential oils had the best anti-C. albicans activity (MIC 59.2-93.5 μg mL-1 ), and limonene (MIC 125.5-188.4 μg mL-1 ) and β-caryophyllene (MIC 104.3-184.2 μg mL-1 ) were involved in this effect. SEM examination revealed that D. decipiens essential oils produced an evident lysis on the fungus. Mosquito repellent activity was demonstrated on Aedes aegypti, a vector of dengue, chikungunya and zika viruses. The repellent activity of leaf essential oils (20 %) was effective within 1-5 h post-treatment (>90 %) and it was stronger (p<0.01) than that of commercial DEET. The evaluation of the four major volatiles (10 % each) produced similar results to those of essential oils. Finally, leaf essential oils showed a moderate antiproliferative activity on the lines OVCAR-3 (LD50 56.5-85.7 μg mL-1 ), and verbenone (LD50 65.3 μg mL-1 ) and β-caryophyllene (LD50 43.6 μg mL-1 ) were linked to this effect.
Collapse
Affiliation(s)
- Yesenia Pacheco-Hernández
- Centro de Investigación en Biotecnología Aplicada, ex-hacienda San Juan Molino carretera estatal Tecuexcomac-Tepetitla Km 1.5, CP 90700, Tlaxcala, México
| | - Gloria Rubí Sánchez-Hernández
- Universidad de la Sierra Sur, Guillermo Rojas Mijangos S/N, Ciudad Universitaria, CP 70800, Miahuatlán de Porfirio Díaz Oaxaca, México
| | - Eric Reyes-Cervantes
- Centro Universitario de Vinculación y Transferencia de Tecnología-DITCo, Benemérita Universidad Autónoma de Puebla, Cd. Universitaria, CP 72570, Puebla, México
| | - Omar Romero-Arenas
- Centro de Agroecología, Instituto de Ciencias, Benemérita, Universidad Autónoma de Puebla, Edificio VAL 1, Km 1,7 carretera a San Baltazar Tetela, San Pedro Zacachimalpa, 72960, Puebla, México
| | - Ivonne Pérez-Xochipa
- Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Cd. Universitaria, CP 72570, Puebla, México
| | - Nemesio Villa-Ruano
- CONACyT-Centro Universitario de Vinculación y Transferencia de Tecnología-DITCo, Benemérita Universidad Autónoma de Puebla, Cd. Universitaria, CP 72570, Puebla, México
| |
Collapse
|
11
|
A Novel CD147 Inhibitor, SP-8356, Attenuates Pathological Fibrosis in Alkali-Burned Rat Cornea. Int J Mol Sci 2020; 21:ijms21082990. [PMID: 32340317 PMCID: PMC7215672 DOI: 10.3390/ijms21082990] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 04/18/2020] [Accepted: 04/22/2020] [Indexed: 12/19/2022] Open
Abstract
The corneal fibrotic responses to corneal damage often lead to severe corneal opacification thereby resulting in severe visual impairment or even blindness. The persistence of corneal opacity depends heavily on the activity of corneal myofibroblast. Myofibroblasts are opaque and synthesize a disorganized extracellular matrix (ECM) and thus promoting opacification. Cluster of differentiation 147 (CD147), a member of the immunoglobulin superfamily, is known to play important roles in the differentiation process from fibroblast to myofibroblast in damaged cornea and may therefore be an effective target for treatment of corneal opacity. Here, we examined the therapeutic efficacy of novel CD147 inhibiting verbenone derivative SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one) on corneal fibrosis. Topical SP-8356 significantly reduced corneal haze and fibrosis in the alkali-burned cornea. In detail, SP-8356 inhibited both alpha-smooth muscle actin (α-SMA) expressing myofibroblast and its ECM-related products, such as matrix-metalloproteinase-9 and collagen type III and IV. Similar to SP-8356, topical corticosteroid (prednisolone acetate, PA) also reduced the ECM-related products and opacification. However, prednisolone acetate failed to decrease the population of α-SMA-positive corneal myofibroblast. In conclusion, SP-8356 is capable enough to prevent corneal haze by preventing pathological fibrosis after severe corneal damage. Therefore, SP-8356 could be a potentially promising therapeutic drug for corneal fibrosis.
Collapse
|
12
|
Zhou Y, Oh MH, Kim YJ, Kim EY, Kang J, Chung S, Ju C, Kim WK, Lee K. Metabolism and Pharmacokinetics of SP-8356, a Novel (1 S)-(-)-Verbenone Derivative, in Rats and Dogs and Its Implications in Humans. Molecules 2020; 25:molecules25081775. [PMID: 32294954 PMCID: PMC7221793 DOI: 10.3390/molecules25081775] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 04/03/2020] [Accepted: 04/09/2020] [Indexed: 01/04/2023] Open
Abstract
(1S,5R)-4-((E)-3,4-dihydroxy-5-methoxystryryl)-6,6-dimethylbicylco[3.1.1]hept-3-en-2-one (SP-8356) is a novel (1S)-(−)-verbenone derivative that is currently in preclinical development for the treatment of ischemic stroke and atherosclerosis. This report aimed at characterization of the metabolism and pharmacokinetic properties of SP-8356. Following intravenous dose in rats and dogs, plasma concentrations of SP-8356 declined rapidly with high clearance (CL) and short half-life; after oral administration in both species, its plasma levels were below the quantitation limit. Fourteen circulating metabolites, formed by mono-oxygenation, demethylation, glucuronidation, catechol O-methylation, sulfation and oxidation (bioactivation) followed by glutathione (GSH) conjugation, were tentatively identified in both species. Urinary excretion of SP-8356 appeared to be minimal in rats, compared to its metabolites. GSH conjugate of SP-8356 was also formed during incubation with rat liver S9 fraction consistent with oxidative bioactivation; this bioactivation was almost completely inhibited by the cofactors for glucuronidation, sulfation and methylation, indicating that it may be abolished by competing metabolic reactions in the body. The human pharmacokinetics of SP-8356 was predicted to be similar to that of the animals based on the current in vitro metabolic stability results. In summary, rapid phase II metabolism appears to be mainly responsible for its suboptimal pharmacokinetics, such as high CL and low oral absorption. Because of competing metabolic reactions, potential safety risks related to SP-8356 bioactivation may be low.
Collapse
Affiliation(s)
- Yuanyuan Zhou
- College of pharmacy, Korea University, Sejong 30019, Korea
| | - Mun Hwan Oh
- College of pharmacy, Korea University, Sejong 30019, Korea
| | - Yeon Joon Kim
- College of pharmacy, Korea University, Sejong 30019, Korea
| | - Eun-yeong Kim
- College of pharmacy, Korea University, Sejong 30019, Korea
| | - Jinhong Kang
- College of pharmacy, Korea University, Sejong 30019, Korea
| | - Sung Chung
- Research Headquarters, Shin Poong Pharm. Co., Ltd., Ansan, Gyeonggi 15610, Korea
| | - Chung Ju
- Research Headquarters, Shin Poong Pharm. Co., Ltd., Ansan, Gyeonggi 15610, Korea
| | - Won-Ki Kim
- Departments of Biomedical Sciences and Neuroscience, College of Medicine, Korea University, Seoul 02841, Korea
- Institute of Inflammation Control, Korea University, Seoul 02841, Korea
| | - Kiho Lee
- College of pharmacy, Korea University, Sejong 30019, Korea
- Institute of Pharmaceutical Science and Translational Research, Korea University, Sejong 30019, Korea
- Biomedical Research Center, Korea University Guro Hospital, Seoul 08308, Korea
- Correspondence: ; Tel.: +82-44-860-1616
| |
Collapse
|
13
|
Pahk K, Joung C, Song HY, Kim S, Kim WK. SP-8356, a Novel Inhibitor of CD147-Cyclophilin A Interactions, Reduces Plaque Progression and Stabilizes Vulnerable Plaques in apoE-Deficient Mice. Int J Mol Sci 2019; 21:ijms21010095. [PMID: 31877775 PMCID: PMC6981359 DOI: 10.3390/ijms21010095] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2019] [Revised: 12/11/2019] [Accepted: 12/18/2019] [Indexed: 12/15/2022] Open
Abstract
Interactions between CD147 and cyclophilin A (CypA) promote plaque rupture that causes atherosclerosis-related cardiovascular events, such as myocardial infarction and stroke. Here, we investigated whether SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one), a novel drug, can exert therapeutic effects against plaque progression and instability through disruption of CD147-CypA interactions in apolipoprotein E-deficient (ApoE KO) mice. Immunocytochemistry and immunoprecipitation analyses were performed to assess the effects of SP-8356 on CD147-CypA interactions. Advanced plaques were induced in ApoE KO mice via partial ligation of the right carotid artery coupled with an atherogenic diet, and SP-8356 (50 mg/kg) orally administrated daily one day after carotid artery ligation for three weeks. The anti-atherosclerotic effect of SP-8356 was assessed using histological and molecular approaches. SP-8356 interfered with CD147-CypA interactions and attenuated matrix metalloproteinase-9 activation. Moreover, SP-8356 induced a decreased in atherosclerotic plaque size in ApoE KO mice and stabilized plaque vulnerability by reducing the necrotic lipid core, suppressing macrophage infiltration, and enhancing fibrous cap thickness through increasing the content of vascular smooth muscle cells. SP-8356 exerts remarkable anti-atherosclerotic effects by suppressing plaque development and improving plaque stability through inhibiting CD147-CypA interactions. Our novel findings support the potential utility of SP-8356 as a therapeutic agent for atherosclerotic plaque.
Collapse
Affiliation(s)
- Kisoo Pahk
- Institute for Inflammation Control, Korea University, Seoul 02841, Korea; (K.P.); (C.J.); (H.Y.S.)
- Department of Neuroscience, Korea University College of Medicine, Seoul 02841, Korea
- Department of Nuclear Medicine, Korea University Anam Hospital, Seoul 02841, Korea;
| | - Chanmin Joung
- Institute for Inflammation Control, Korea University, Seoul 02841, Korea; (K.P.); (C.J.); (H.Y.S.)
- Department of Neuroscience, Korea University College of Medicine, Seoul 02841, Korea
| | - Hwa Young Song
- Institute for Inflammation Control, Korea University, Seoul 02841, Korea; (K.P.); (C.J.); (H.Y.S.)
- Department of Neuroscience, Korea University College of Medicine, Seoul 02841, Korea
| | - Sungeun Kim
- Department of Nuclear Medicine, Korea University Anam Hospital, Seoul 02841, Korea;
| | - Won-Ki Kim
- Institute for Inflammation Control, Korea University, Seoul 02841, Korea; (K.P.); (C.J.); (H.Y.S.)
- Department of Neuroscience, Korea University College of Medicine, Seoul 02841, Korea
- Correspondence: ; Tel.: +82-2-2286-1095; Fax: +82-2-953-6095
| |
Collapse
|
14
|
Pahk K, Noh H, Joung C, Jang M, Song HY, Kim KW, Han K, Hwang JI, Kim S, Kim WK. A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation. J Transl Med 2019; 17:274. [PMID: 31429778 PMCID: PMC6700999 DOI: 10.1186/s12967-019-2024-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2018] [Accepted: 08/14/2019] [Indexed: 12/20/2022] Open
Abstract
Background Neointimal hyperplasia and its related arterial stiffness are the crucial pathophysiological features in atherosclerosis and in-stent restenosis. Cluster of differentiation 147 (CD147), a member of the immunoglobulin super family that induces the expression of matrix metalloproteinase-9 (MMP-9) by dimerization, may play important roles in neointimal hyperplasia and may therefore be an effective target for the treatment of this condition. Here, we investigated whether a novel CD147 inhibitor SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one) reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation. Methods Neointimal hyperplasia was induced in Sprague–Dawley rats by partial ligation of the right carotid artery combined with a high fat diet and vitamin D injection. Rats were subdivided into vehicle, SP-8356 (50 mg/kg), and rosuvastatin (10 mg/kg) groups. The drugs were administrated via intraperitoneal injections for 4 weeks. The elasticity of blood vessels was assessed by measuring pulse wave velocity using Doppler ultrasonography before sacrifice. Histomolecular analysis was carried out on harvested carotid arteries. Results SP-8356 significantly reduced MMP activity by inhibiting CD147 dimerization. SP-8356 reduced neointimal hyperplasia and prevented the deterioration of vascular elasticity. SP-8356 had a greater inhibitory effect on neointimal hyperplasia than did rosuvastatin. Furthermore, rosuvastatin did not improve vascular elasticity. SP-8356 increased the expression of smooth muscle myosin heavy chain (SM-MHC), but decreased the expression of collagen type III and MMP-9 in the neointimal region. In contrast to SP-8356, rosuvastatin did not alter the expression of SM-MHC or MMP-9. Conclusions The ability of SP-8356 to reduce neointimal hyperplasia and improve arterial stiffness in affected carotid artery suggests that SP-8356 could be a promising therapeutic drug for vascular remodeling disorders involving neointimal hyperplasia and arterial stiffness.
Collapse
Affiliation(s)
- Kisoo Pahk
- Institute for Inflammation Control, Korea University, Seoul, South Korea.,Department of Neuroscience, Korea University College of Medicine, 126-1, Anam-Dong 5-Ga, Seongbuk-Gu, Seoul, 136-705, South Korea.,Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, South Korea
| | - Hyojin Noh
- Institute for Inflammation Control, Korea University, Seoul, South Korea.,Department of Neuroscience, Korea University College of Medicine, 126-1, Anam-Dong 5-Ga, Seongbuk-Gu, Seoul, 136-705, South Korea
| | - Chanmin Joung
- Institute for Inflammation Control, Korea University, Seoul, South Korea.,Department of Neuroscience, Korea University College of Medicine, 126-1, Anam-Dong 5-Ga, Seongbuk-Gu, Seoul, 136-705, South Korea
| | - Mi Jang
- Institute for Inflammation Control, Korea University, Seoul, South Korea.,Department of Neuroscience, Korea University College of Medicine, 126-1, Anam-Dong 5-Ga, Seongbuk-Gu, Seoul, 136-705, South Korea
| | - Hwa Young Song
- Institute for Inflammation Control, Korea University, Seoul, South Korea.,Department of Neuroscience, Korea University College of Medicine, 126-1, Anam-Dong 5-Ga, Seongbuk-Gu, Seoul, 136-705, South Korea
| | - Kyung Won Kim
- Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Kihoon Han
- Institute for Inflammation Control, Korea University, Seoul, South Korea.,Department of Neuroscience, Korea University College of Medicine, 126-1, Anam-Dong 5-Ga, Seongbuk-Gu, Seoul, 136-705, South Korea
| | - Jong-Ik Hwang
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul, South Korea
| | - Sungeun Kim
- Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, South Korea
| | - Won-Ki Kim
- Institute for Inflammation Control, Korea University, Seoul, South Korea. .,Department of Neuroscience, Korea University College of Medicine, 126-1, Anam-Dong 5-Ga, Seongbuk-Gu, Seoul, 136-705, South Korea.
| |
Collapse
|